Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | PDE5A | O76074 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940926 | 0.90 | PRKCZ (0.58) | PTGS2MEN1KMT2AL3MBTL1PRKCZ | |
| SCHEMBL4946878 | 0.86 | PRKCZ (0.56) | PTGS2MEN1KMT2AL3MBTL1PRKCZ | |
| SCHEMBL4945056 | 0.82 | PTGS2 (0.64) | PTGS2PDE5AL3MBTL1PRKCZCA1 | |
| SCHEMBL4940790 | 0.81 | PRKCZ (0.56) | PTGS2PRKCZCA1CA2 | |
| SCHEMBL4948095 | 0.80 | MEN1 (0.61) | MEN1KMT2AL3MBTL1PRKCZCA1 | |
| SCHEMBL4946809 | 0.75 | MAOB (0.59) | PRKCZ | |
| SCHEMBL4947365 | 0.75 | PRKCZ (0.42) | PTGS2PRKCZCA1CA2 | |
| SCHEMBL4942223 | 0.75 | ESD (0.55) | PTGS2MEN1KMT2AL3MBTL1PRKCZ | |
| SCHEMBL12494514 | 0.74 | PDE5A (1.00) | PDE5APRKCZ | |
| SCHEMBL31574476 | 0.72 | PTGS2 (0.64) | PTGS2PDE5AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435750-B2 | Method of using substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | PTGS2 2033/4885PDE5A 2105/4885MEN1 3494/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | PTGS2 2222/4885PDE5A 2503/4885MEN1 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.